JPRN-jRCT2031210570
Active, not recruiting
Phase 3
AYD001 Phase III Clinical Trial - AYD001/CT1
Asaoka Kuniharu0 sites60 target enrollmentJanuary 21, 2022
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Patients with chronic renal failure undergoing hemodialysis
- Sponsor
- Asaoka Kuniharu
- Enrollment
- 60
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Patients undergoing hemodialysis for 3 to 5 hours per session, 3 times a week at the time of informed consent.
- •(2\) Patients aged 20 to less than 90 years old.
- •(3\) Patients providing written informed consent about participation in this clinical study
Exclusion Criteria
- •(1\) Patients within 26 weeks of initiating hemodialysis at the time of informed consent
- •(2\) Patients with severe hepatic function impairment
- •(3\) Patients with severe heart disease
- •(4\) Patients with severe respiratory disorder
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
Unknown
Phase 3
Phase 3 Clinical Trial with MD-0901JPRN-jRCT2080222425MOCHIDA PHARMACEUTICAL CO., LTD.250
Active, not recruiting
Not Applicable
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMInborn errors of metabolismMedDRA version: 9.1Level: LLTClassification code 10062018Term: Inborn error of metabolismEUCTR2009-011921-15-NLAldagen, Inc40
Active, not recruiting
Not Applicable
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMEUCTR2009-017026-39-NLAldagen, Inc40
Completed
Phase 3
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMNL-OMON32439Aldagen, Inc.12